Education
About Us
Working with TipRanks
Follow Us
Virbac SA (GB:0NM7)
:0NM7
0NM7 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€255.00 - €399.00
Previous CloseN/A
Volume98.00
Average Volume (3M)492.00
Market Cap
€2.45B
Enterprise Value€2.98B
Total Cash (Recent Filing)€62.81M
Total Debt (Recent Filing)€486.71M
Price to Earnings (P/E)16.8
Beta0.71
Next Earnings
Sep 12, 2025EPS EstimateN/A
Last Dividend Ex-Date
Jun 25, 2024Dividend Yield0.45%
Share Statistics
EPS (TTM)17.35
Shares Outstanding8,390,660
10 Day Avg. Volume48
30 Day Avg. Volume492
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)N/A
Price to Sales (P/S)2.24
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€375.33Price Target Upside29.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Virbac SA News
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceVirbac published reassuring figures for H2-24, leading the group to slightly beat expectations on FY24 EBIT adj.
Growth PotentialExposures to emerging countries like India and Mexico are enabling an acceleration in the group's growth pace as the growing middle class in these countries and their purchasing power are fuelling the animal health sector.
Market PositionVirbac is the world's sixth-largest veterinary medicines producer with a wide range of veterinary products including medicines and specialised food for companion and farm animals.
Bears Say
Earnings GrowthSlowdown of earnings growth likely to continue in H1-25 due to an unfavourable base effect.
Economic EnvironmentConcerns exist about the economic environment as the group embarks on a major investment programme and searches for a new CEO, making it premature to turn more positive currently.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
6.19%
Mutual Funds
― Other Institutional Investors
90.94% Public Companies and
Individual Investors
0NM7 FAQ
What was Virbac SA’s price range in the past 12 months?
Virbac SA lowest share price was €255.00 and its highest was €399.00 in the past 12 months.
What is Virbac SA’s market cap?
Virbac SA’s market cap is €2.45B.
When is Virbac SA’s upcoming earnings report date?
Virbac SA’s upcoming earnings report date is Sep 12, 2025 which is in 151 days.
How were Virbac SA’s earnings last quarter?
Virbac SA released its earnings results on Mar 13, 2025. The company reported €6.044 earnings per share for the quarter, beating the consensus estimate of N/A by €6.044.
Is Virbac SA overvalued?
According to Wall Street analysts Virbac SA’s price is currently Undervalued.
Does Virbac SA pay dividends?
Virbac SA pays a Annually dividend of €1.319 which represents an annual dividend yield of 0.45%. See more information on Virbac SA dividends here
What is Virbac SA’s EPS estimate?
Virbac SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Virbac SA have?
Virbac SA has 8,390,660 shares outstanding.
What happened to Virbac SA’s price movement after its last earnings report?
Virbac SA reported an EPS of €6.044 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.972%.
Which hedge fund is a major shareholder of Virbac SA?
Currently, no hedge funds are holding shares in GB:0NM7
---
Company Description
Virbac SA
Virbac SA is a major drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, followed by North America and Latin America. Most of the company's sales are generated from its Companion Animals segment, followed by its Food Producing Animals segment. Veterinarians remain Virbac's main client, yet the company's clients are particularly diverse throughout the world in terms of profession, size and expectations. Virbac's strategy focuses on dominating niche markets while either avoiding or remaining differentiated within the more competitive markets.
---
0NM7 Stock 12 Month Forecast
Average Price Target
€375.33
▲(29.09% Upside)
Technical Analysis
Best Analysts Covering 0NM7
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-10.10%
upgraded a buy rating 29 days ago
Copying Valentin Paul Jahan's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -10.10% per trade.
---